Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest
Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases
First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study
Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.